Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03859492 · ClinicalTrials.gov registry record · NA
Screening CEDM in Intermediate and High-Risk Patient Populations
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 461
- Enrollment target
NCT03859492: Completed NA study, sponsored by Mayo Clinic.
NCT03859492 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 461 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03859492, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 461 participants
- Enrollment target
Study Summary
This research study is being done to determine if Contrast Enhanced Digital Mammography (CEDM) can improve breast cancer detection and can be used as an additional screening method to the standard mammographic screening.
Primary Outcome
Number of subjects diagnosed with breast cancer
Interventions
- DEVICE Contrast Enhanced Digital Mammography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 461 participants |
| Start Date | 2019-02-15 |
| Est. Completion | 2021-05-31 |
| Phase | NA |
What the finished NCT03859492 record still lists
NCT03859492 is an interventional study that assigns participants to a tested intervention. The registered 461 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which Contrast Enhanced Digital Mammography is the first listed.
NCT03859492 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03859492 about?
NCT03859492 is a clinical study titled "Screening CEDM in Intermediate and High-Risk Patient Populations". This research study is being done to determine if Contrast Enhanced Digital Mammography (CEDM) can improve breast cancer detection and can be used as an additional screening method to the standard mammographic screening.
What is the current status of trial NCT03859492?
This trial is currently completed. It is a NA study. The enrollment target is 461 participants. The study started on 2019-02-15. Estimated completion is 2021-05-31.
What interventions are being tested in trial NCT03859492?
The interventions under investigation include: Contrast Enhanced Digital Mammography (DEVICE).
Who is sponsoring clinical trial NCT03859492?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03859492's enrollment target sits among peer trials
461 222nd of 2000 higher than 1,779 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04546399 · 461 participants · Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT00949819 · 462 participants
Active Surveillance for Cancer of the Prostate (ASCaP)
- NCT05126277 · 462 participants · Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI